Ignite Creation Date:
2025-12-24 @ 7:22 PM
Ignite Modification Date:
2025-12-31 @ 4:17 AM
Study NCT ID:
NCT03112603
Status:
COMPLETED
Last Update Posted:
2025-08-12
First Post:
2017-04-04
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Sponsor:
Incyte Corporation
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-06-29
Start Date Type:
ACTUAL
Primary Completion Date:
2020-05-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-12-15
Completion Date Type:
ACTUAL
First Submit Date:
2017-04-04
First Submit QC Date:
None
Study First Post Date:
2017-04-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2021-12-10
Results First Submit QC Date:
None
Results First Post Date:
2022-04-15
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2022-04-15
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2025-08-08
Last Update Post Date:
2025-08-12
Last Update Post Date Type:
ACTUAL